Indomethacin Enhances the Cytotoxicity of VCR and ADR in Human Pulmonary Adenocarcinoma Cells.
- 1 January 1997
- journal article
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 181 (3), 361-370
- https://doi.org/10.1620/tjem.181.361
Abstract
The ability of anti-inflammatory agents to modulate cellular sensitivity to anticancer drugs was investigated for pulmonary carcinoma cells in vitro. We examined the drug sensitivity of two pulmonary adenocarcinoma cell lines (76-2, 77-4) in the presence of two drugs, an anticancer drug and an anti-inflammatory agent, for 72 hr by the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay with 96 well plates. Anticancer drugs used for screening test were cyclophosphamide (CPM), mitomycin C (MMC), adriamycin (ADR), 5-fluorouracil (5FU), vindesine (VDS), cisplatin (CDDP), cytarabine (Ara C), methotrexate (MTX), etoposide (VP-16), and vincristine (VCR). Anti-inflammatory agents examined as modulators to anticancer drugs were aspirin, mefenamic acid, ibuprofen, sulindac, piroxicam, phenacetin, dicrofenac, ketoprofen, tolmetin and indomethacin. Screening tests showed indomethacin to be the most effective modulator, resulting in more than a 3-fold increase in cytotoxicity of VCR as compared with that produced by VCR alone. Study of each of the ten anticancer drugs in combination with indomethacin showed VCR to be the most effective anticancer drug in this combination. In 76-2 cells, the concentration of VCR producing 50% growth inhibition (IC50) for VCR alone and VCR in combination with 2 micrograms/ml indomethacin were 1.58 +/- 0.16 and 0.52 +/- 0.1 ng/ml respectively, which represents a 3-fold decrease. In 77-4 cells, the IC50 for VCR alone and VCR in combination with 2 micrograms/ml indomethacin were 2.86 +/- 0.2 and 0.52 +/- 0.11 ng/ml respectively, which represents a 3.8-fold decrease. Our studies indicate that clinically achievable concentrations of indomethacin may be useful in modulating VCR resistance in human pulmonary adenocarcinoma cells, so that combined use of VCR and indomethacin may be of potential clinical significance in the treatment of lung cancer.Keywords
This publication has 13 references indexed in Scilit:
- Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.Journal of Clinical Oncology, 1995
- Syalil-SSEA1(SLX) Levels in Supernatant of Cultured Human Lung Carcinoma Cell Lines.The Tohoku Journal of Experimental Medicine, 1994
- A Convenient and Inexpensive Chemo-Radiosensitivity Assay for Lung Cancer Cells Using Terasaki's Microplate.The Tohoku Journal of Experimental Medicine, 1993
- Characterization and the Clinical Application of Cultured Human Pulmonary Carcinoma Cells.The Tohoku Journal of Experimental Medicine, 1992
- Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma.Journal of Clinical Oncology, 1991
- Culture and changes in dynamics of proliferation of pulmonary small cell carcinoma cells.The Tohoku Journal of Experimental Medicine, 1989
- Role of the Glutathione Redox Cycle in Acquired and de Novo Multidrug ResistanceScience, 1988
- Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexateBritish Journal of Pharmacology, 1987
- Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasisCellular Immunology, 1986
- A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations.British Journal of Clinical Pharmacology, 1982